The Effects of Phosphatidylserine (PS) Expression on HL 60, and the Efficacy of the Role of Doxorubicin (DOX) on HL60

Mohammad Alshugeer*, Hesham H Ameen and Abdullah Alhassoon

Ministry of Health, KSA

*Corresponding author: Mohammad Alshugeer, Ministry of Health, Riyadh, KSA.

To Cite This Article: Mohammad Alshugeer. The Effects of Phosphatidylserine (PS) Expression on HL 60, and the Efficacy of the Role of Doxorubicin (DOX) on HL60. Am J Biomed Sci & Res. 2019 - 3(3). AJBSR.MS.ID.000668. DOI: 10.34297/AJBSR.2019.03.000668

Received: May 25, 2019 | Published: June 10, 2019

Abstract

Introduction: In recent studies the importance has been shown of the interactions between CD47 expressed on HL60 cells and the inhibitory Protein Kinase C (PKC) (Bisindolylmaleimide I).

Study objectives: The study aimed to explore the function of CD47 expressed on HL60 cells and the inhibitory Protein Kinase C (PKC).

Methodology: Initially, the expression of Phosphatidylserine (PS) levels in HL60 was analysed. The effect of PS expression on tumour cell growth and programmed cell death was also examined by triggering with BRIC-126 antibody. At the same time, we were able to observe the efficacy of doxorubicin (DOX) on HL60 when combined with other established leukemic drugs. The HL60 cell lines were analysed using flow cytometry to find out how PKC (Bisindolylmaleimide I) was expressed in HL60 and whether that expression was dependent on whether PKC is activated or inhibited. Although the efficacy of DOX on HL60 was clearly demonstrated by the research, the mechanism through which it worked was not clearly demonstrated.

Study Findings: There was an agreement with the view that PKC may have an anti-leukemic effect, and that it may potentially be a therapeutic target in neoplastic cells. Although this would require further research specific to those areas, the data collected also tended to agree with the view that DOX could be a useful treatment for some malignant diseases.

Conclusion: The results of the present study showed the potential of using PKC as an anti-leukemic therapeutic option.

Keywords: PKC; Malignant disease; Doxorubicin; CD47; HL60; Phosphatidylserine; Flow cytometry

Introduction

Phagocytosis, which entails removal of dying, damaged or altered cells, is an essential mechanism for haemostasis. The clearance of aged cells is characterized by a conformational change in Cluster of Differentiation 47 (CD47) due to autoantibody binding to Band 3, and appearance of phosphatidylserine (PS) on the outer leaflet of the cell membrane [1-3]. CD47, also known as integrin-associated protein (IAP), is a transmembrane protein of the immunoglobulin (Ig) superfamily, which is heavily glycosylated and expressed by all cells in the body [3]. CD47 controls immune responses, cell spreading and adhesion by binding to thrombospondin-1 (TSP1) [4] and communicates with transmembrane signal-regulatory proteins (SIRPα) receptors on macrophages to give off a “don’t eat me” signal which plays a critical role in cellular processes, including apoptosis, proliferation, adhesion and migration [5,6].

Cancer cells evade phagocytic elimination by cell surface up-regulation of phagocyte-inhibitory signals, such as CD47 [3]. Overexpression of CD47 promotes survival of the neoplastic cells in solid and haematological malignancies [7-9]. Blockade of CD47-SIRPα interaction enhances phagocytic elimination of CD47 over-expressing tumour cells [7,10]. Recent studies have shown that ligation of CD47 with monoclonal antibodies (mAbs) and the specific CD47-binding peptide 41NK, derived from TSP-1, can induce caspase-independent cell death characterized by cytoskeleton remodelling and phosphatidylserine (PS) expression on the cell surface [11-13].

Externalisation of phosphatidylserine (PS) to the outer membrane, another hallmark of apoptosis and phagocytosis,
occurs as a result of reduced amino phospholipid translocase activity and activation of a calcium-dependent scramblase [14,15]. In the early stages of apoptosis, inhibition of translocase, in part due to an elevation in intracellular Ca2+ and activation of a lipid scramblase, allows the appearance of PS on the surface of the cells [16]. There are a number of PS-binding proteins that can act as a bridge between apoptotic cells and phagocytes such as plasma-protein β2-glycoprotein I, the product of growth arrest-specific gene 6 (Gas6) that binds to the Mer kinase and the protein milk-fat globule epidermal growth factor 8 that bridge with vitronectin receptor integrin (αvβ3) and protein S that binds PS [17,18].

The protein kinase C (PKC), a ubiquitous cellular enzyme, is a family of homologous serine/threonine kinases [19]. There are at least 11 isoforms that are divided into three groups according to their second messenger requirements: classical, novel, and atypical [20]. PKC plays an important role in signal transduction in response to the production of diacylglycerol (DAG). PKC has also been associated with numerous physiological functions, including secretion and exocytosis, modulation of ion conductance, gene expression, and cell proliferation [21]. Activation of PKC has also been reported to be crucial to tumour growth. However, the bisindolylmaleimide derivatives of staurosporine are widely used as specific inhibitors of protein kinase C (PKC) isoforms. Bisindolylmaleimide I (Bis I), the most commonly used PKC inhibitor, can block PKC activity by competitively inhibiting its ATP binding ability [22,23]. It also inhibits cAMP- and cGMP-dependent protein kinase [24].

A study by Gobbi et al. [25] showed that using PKC inhibitors as anti-cancer agents, particularly in acute myeloid leukaemia (AML), may be possible and requires further investigation. The HL60 (Human promyelocytic leukaemia cells) cell line has been used for laboratory research on how certain kinds of blood cells are formed. HL-60 cells proliferate continuously in suspension culture in nutrient medium supplemented with foetal bovine serum, L-glutamine, HEPES and antibiotic chemicals. The doubling time is about 36–48 hours. The cell line was derived from a 36-year-old woman with acute promyelocytic leukaemia. HL-60 cells are predominantly a neutrophilic promyelocyte [26].

The HL60 cultured cell line provides a continuous source of human cells for studying the molecular events of myeloid differentiation and the effects of physiologic, pharmacologic, and virologic elements on this process. HL60 cell model was used to study the effect of DNA topoisomerase (topo) Iα and IIβ on differentiation and apoptosis of cells [27]. Doxorubicin (DOX) is an anthracycline antibiotic used in treatment of various human neoplastic diseases including leukemias, lymphomas, sarcomas, carcinomas and breast cancers [28]. It exerts its antitumor effects primarily via DNA intercalation and topoisomerase II inhibition thereby leading to apoptosis (Bao et al., 2012).

The observations, from Gobbi et al. [25] prompted the hypothesis that Bis I may play a role in CD47-mediated cell death. Herein, the author investigated the effect of Bis I on expression of phosphatidylserine (PS) following CD47-mediated cell death and cell surface expression of CD47 in HL60 acute promyelocytic cell line. These tests were carried out with and without the presence of DOX; this effectively also tests the efficacy of DOX in these situations.

**Study objectives**

The aim of this project is to provide supportive evidence of the effect of protein kinase C inhibitor (Bisindolylmaleimide I) on expression of phosphatidylserine (PS).

**Materials and Methods**

**Cell culture**

HL60 cells were used throughout the experiment. The cells were cultured in RPMI 1640 medium supplemented with L-glutamate (2mM) and 10% FCS. Cells were maintained at 37°C in a humidified atmosphere with 5% CO2-95% air (NuAIRE Direct Heat Airflow). Cells were maintained between 1x105 and 1x106 cells/mL in T25 culture flasks by sub-culturing twice. Cells (in RPMI 1640 medium) were centrifuged at 300g for five minutes before washing the cell pellet with 5 ml of PBS. Next, the cell solution was centrifuged at 300g for five minutes and the cells re-suspended in fresh culture media.

**Cell Count**

HL60 cells (20μl) were uniformly stained with 20μl of 0.4% (w/v) trypan blue (Sigma-Aldrich Poole, UK) and counted with a haemocytometer. Cell count was calculated using the formula:

\[
\text{Number of cells in single large square X2 (the dilution factor with trypan blue also x104cells/ml)}. \]

**Flow Cytometry**

Flow cytometry was carried out using a BD Accuri C6 flow cytometer (BD Biosciences, Oxford, UK) equipped with a digital laser. Approximately 10,000 cells were analysed from each treatment. Data analysis was performed using CFlow Plus software.

**Annexin-V FITC Binding Assay**

According to Pollard [29], testing the interaction between molecules is “one of the most common tests” in cellular and molecular biology. Assaying the level of interaction is always quantitative – it is never simply a yes or no answer. Thus, this assay will measure the quantity of cells that have been stained – these are the cells in which interaction has taken place.

With modifications of Jeremy et al. [13] methods, 1 x 106/mL HL60 cells were washed twice with HBSS and reconstituted in HBSS. Cells were incubated in 96-well plates with 1μl of Bisindolylmaleimide I (Bis I) (protein kinase inhibitor) for 30 minutes before incubating with 5μl of BRIC-126 or BRIC-235 overnight at room temperature on an orbital shaker. Following incubation, cells were washed twice in HBSS followed by washing in 1xAnnexin V-FITC binding buffer and re-suspended in 1xAnnexin V-FITC binding buffer. Cells were then incubated with Annexin V-FITC (5μl) for 15 minutes in the dark at room temperature. Samples were transferred to eppendorf tubes containing 1xAnnexin V-FITC binding buffer (300μl) placed on ice, prior to staining with PI and flow cytometric data analysis for PS exposure.
Doxorubicin Assay

Like the binding assay, this is a quantitative assessment of the number of cells affected in each sample; like the binding assay its accuracy and dependency are regarded as high, since the advice of other experts in the field was followed to ensure that this was the case, and to ensure there were no flaws in the design of the assay [29]. Enough suspension cells were recovered to complete assay; a stock of doxorubicin was diluted in RPMI culture media to produce different concentrations (50-500µM). The cells were washed with HBSS and diluted in RPMI culture media to a concentration of 7x105/ml. The cells were placed in a 24-well plate (1ml per well) and mixed with different concentrations (50-500µM) of doxorubicin before incubating them for up to 72hours at 37°c in a humidified atmosphere with 5% CO2-95% air, with cells analysed at 0 hours, 24hours, 48hours and 72hours after adding doxorubicin.

After doxorubicin treatment, the cells were washed with HBSS and mixed with PBS before staining them with anti-human CD47-FITC (5μl) from BD Biosciences, Oxford, UK. Subsequently, the cells were incubated in the dark for 15minutes at room temperature. After incubation, samples were transferred to eppendorf tubes containing PBS (300μl) and placed on ice, followed by flow cytometric data analysis for surface expression of CD47.

Results

The effect of DOX on CD47 expression and the role of PKC in CD47-mediated PS exposure were investigated and the following results were obtained.

Bisindolylmaleimide I enhance CD47-mediated cell death in HL60 cells

To ascertain the role of bisindolylmaleimide I in externalization of PS to outer surface of HL60 cells (between 1x105 and 1x106 cells/ml concentration), HL60 cells were treated with 1μl of bisindolylmaleimide I, 5μl of BRIC-126 or BRIC-235 overnight at 37oC in an orbital shaker and stained with annexin-V FITC (5μl). Controls (Figure 1A/B) were stained with only annexin-V and PI. Ligation of CD47 with BRIC-126 (Figure 1C) or BRIC 235 without bisindolylmaleimide (Figure 1E) triggered CD47-mediated cell death in HL60 cells, which became enhanced following treatment with bisindolylmaleimide I (Figure 1D & 1F).

HL60 cells express increased surface CD47 with DOX

HL60 cells were treated with increasing concentrations (50 to 500µM) of doxorubicin and incubated for 72 hours. Following the procedure used by other researchers, the controls were left unstained, whilst the isotype controls were treated with anti-CD47 FITC. In comparison to the control, HL60 expressed an increased level of surface CD47 at all concentrations of doxorubicin after 0 hours, with highest CD47 expression at 50µM. However, after 72 hours the control cells still expressed a high level of surface expression whilst treated cells expressed reduced surface CD47 expression. The relative percentage surface CD47 expression by HL60 cells following treatment with doxorubicin is shown in Figure 2 & 3.

Figure 1: Bisindolylmaleimide I enhances CD47-mediated cell death in HL60 acute promyelocytic leukaemia cell line. HL60 cells (1 x 106/ml) were incubated overnight with monoclonal antibodies and bisindolylmaleimide I. Cell surface expression of PS was measured by flow cytometry following staining with annexin-V. Each experiment was repeated three times (n=3).
Figure 2: Doxorubicin causes an increase in expression of CD47 in HL60 cells. Here, representative plots of surface CD47 expression by flow cytometry immediately following treatment with increasing concentrations (50μM to 500μM) of doxorubicin at 0 hours are shown. Histograms show a shift in CD47 expression from control (untreated HL60 cells) after treatment with doxorubicin. Each experiment was repeated three times (n=3).

Figure 3: Doxorubicin causes a decrease in expression of CD47 in HL60 cells. Here, representative plots of surface CD47 expression by flow cytometry following treatment with increasing concentrations (50μM to 500μM) of doxorubicin after 24 hours are shown. Histograms show a reduction in CD47 expression from control (untreated HL60 cells) after treatment with doxorubicin. Each experiment was repeated three times (n=3).

Figure 1 shows a series of histograms (A to F) showing fluorescence concentration in the samples when incubated overnight. Figure 1 A represents HL-60 cells with bisindolylmaleimide I and Figure 1B represents HL-60 cells without bisindolylmaleimide I. Figure 1C is the histogram after overnight incubation of HL-60 cells with BRIC-126 and Figure 1D HL-60 cells with bisindolylmaleimide I. The final pairs in the illustration are Figure 1E, HL-60 cells with BRIC-256 and Figure 1F, HL-60 cells with bisindolylmaleimide I. Each of these experiments was repeated three times to obtain mean or average figures. Figure 2 consists of six histograms following the flow cytometry. This set of figures was obtained immediately after introduction (0 Hours) and each histogram is labelled with the...
concentration. At this point, it appears that the introduction of DOX has actually induced an increase in the expression of CD47. This is not unexpected and is in line with previous findings.

Figure 3 reproduces Figure 2 but represents the same samples 24 hours after introduction. Here it can immediately be seen that a reduction of CD47 expression has been induced, but it also clear that the fluorescence is occurring over a wider spectrum, so that although the peak is lower, the width is wider.

Figure 4 show the same samples 48 hours after introduction. When compared directly to Figure 3, it can be seen that there is a slight increase of expression of CD47, but that, once more the spectrum is wider.

Figure 4: Doxorubicin causes a decrease in expression of CD47 in HL60 cells. Here, representative plots of surface CD47 expression by flow cytometry following treatment with increasing concentrations (50μM to 500μM) of doxorubicin after 48 hours are shown. Histograms show a decrease in CD47 expression from control (untreated HL60 cells) after treatment with doxorubicin. Each experiment was repeated three times (n=3).

Figure 5: Expression of surface CD47 by HL60 cells reduced after 72 hour incubation. Representative plots of surface CD47 expression by flow cytometry following treatment with increasing concentrations (50μM to 100μM) of doxorubicin after 72 hours are shown. Histograms show surface CD47 expression by HL60 cells reduced after 72-hour incubation with doxorubicin. Each experiment was repeated three times (n=3).
Finally, Figure 5 shows the samples after 72 hours. These figures also show a slight increase in expression of CD47, but spectrum width has returned to levels comparable with the 0 hour samples.

**Discussion**

In this study, determination of PS exposure was measured to study the effect of Protein Kinase C inhibitor (Bisindolylmaleimide I). This aspect of PKC activity was explained in many studies (Versteeg et al., 2013; Wagner-Britz et al., 2013; Wood et al., 2013 amongst others) and it has important therapeutic implications since induction of mortality by terminal differentiation represents an alternative approach to cytodestruction of cancer cells by conventional antineoplastic agents, and is therefore important biologically. In this respect, Bisindolylmaleimide I is clearly seen in the structure of PKC [30] residue 574-turn motif, need to be phosphorylated towards a PKC-beta-specific inhibitor site-directed mutagenesis of the compound for its full activation [31] and co-crystallized as an asymmetric pair which is mediated by 3-phosphoinositide-dependent protein kinase-1 [32].

However, while Bisindolylmaleimide I are currently evaluated in the treatment of the neoplastic cells, able to induce leukemic cells in other subtypes [33] In this work, it was attempted to find a biochemical explanation for the fact that DOX is active against HL60 cells, which are known for the presence of altered topoisomerase II. The presence of a formamidine group containing morpholine or hexamethyleneimine ring at the 3‘ position enhances the uptake of anthracycline drugs by HL60 cells. This effect is especially pronounced in the case of DOX. Therefore, it can be concluded that addition of a morpholine ring in formamidinoanthracylines significantly enhances the ability of this drug to penetrate cell membranes. The reduced uptake of DOX by HL60 cells may explain why this drug was approximately two times less cytotoxic against this cell line when compared with HL60 cells. The effect of DOX and its derivatives on supercoiled DNA cleavage by topoisomerase II in a cell-free system indicated that contrary to the effect of DOX do not stabilize the degradable complex of topoisomerase II with DNA Thus, it may be concluded that topoisomerase II is not the primary target of DOX and that high cytotoxic activity of these compounds toward HL60 cell line is due to a mechanism of action, which is not related to DNA topoisomerase II inhibition.

Other research into the effects of CD47 on HL60 which is comparable with the results discussed above includes work by Head et al. [12]; Gonelli et al. (2009); Roberts et al. (2013) and Oldenborg [3]. Each of these researchers appears to have worked with a single concentration rather than the four concentrations of the experiments carried out for this research. However, despite this difference their findings appear to be largely in agreement with the results obtained here. While the PKC inhibitor peptide The PKC BIM complex interacts with the zinc finger of lambda/iota PKC characterization of lambda-interacting protein (LIP) [34]. Lambda-interacting protein is a selective activator of lambda/iota PKC. Phosphorylation of a PKC induces a conformation leading to import of a PKC into the nucleus [35] the entire 587-amino acid coding region of a new PKC isoform, PKC-iota [36]. The bound BIM inhibitor blocks the ATP-binding site and puts the kinase domain into an intermediate open conformation [37]. The value of such calculations lies in understanding a variant was designed which showed improved binding characteristics of configurationally stable atropisomeric bisindolylmaleimides [38].

In other research, it showed negligible effects of Bisindolylmaleimide induction of leukemic maturation, this does exclude that the association of PKC inhibitor might represent an important therapeutic combination. In this respect, it is also noteworthy that the PKC inhibitor was able to significantly modulate the degree of apoptosis induced in vivo. The resistance of leukemic cells to currently used therapies occurs in part because leukemic cells safeguard their survival through mechanisms that allow them to escape death receptor-mediated apoptosis [39]. Much attention has recently attracted the protein kinase inhibitor for its ability to overcome resistance to apoptosis in several tumors, including hematological malignancies [40].

While many studies have demonstrated that resistance in a variety of hematological malignancies is mainly due to constitutively level of CD47 and protein kinase C [40], it has demonstrated that also the selective activation of the PKC family member can markedly counteract the susceptibility to cytotoxicity in the HL60 cell line. Current findings are in line with those recently described by [25], who demonstrated that PKC activation by phorbol esters confers resistance to apoptosis induction in the leukemic cell line. However, an important difference between the study of [25] and current data is that inhibitor which was used might have important future clinical applications. In fact, [41] have recently reviewed the potential use of PKC developed by important pharmaceutical companies, which specifically inhibit PKC and ameliorate pathological conditions in a rodent insulin resistance model.

Another experimenter who carried out a similar experiment with similar concentrations [42] also had results which were not hugely different, leading the researcher to comment that the results obtained seemed dependent on the type of cell being studies, but that the role of calpains in CD47-mediated cell death was heterogeneous [42], and that CD47 played a role in MDR development in HEL cells [43-52].

**Conclusions**

The results of the present study showed the potential of using PKC as anti-leukemic therapeutic option. Other studies are required to confirm our data.

**References**


42. Arnize (2014) Personal Communication referring to his own experiment.


